{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:48:26Z","timestamp":1787730506529,"version":"build-2784847793"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.hoc.2025.07.010","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:14:51Z","timestamp":1762928091000},"page":"117-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Gregory C.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.hoc.2025.07.010_bib2","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.hoc.2025.07.010_bib3","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.hoc.2025.07.010_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archsurg.1985.01390320023003","article-title":"Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection","volume":"120","author":"Kalser","year":"1985","journal-title":"Arch Surg"},{"issue":"5","key":"10.1016\/j.hoc.2025.07.010_bib5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0959-8049(05)80349-1","article-title":"Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study","volume":"29A","author":"Bakkevold","year":"1993","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2025.07.010_bib6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.010_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.hoc.2025.07.010_bib8","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2025.07.010_bib9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"issue":"10041","key":"10.1016\/j.hoc.2025.07.010_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.hoc.2025.07.010_bib11","volume":"34","author":"Neoptolemos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2025.07.010_bib12","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2025.07.010_bib13","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.hoc.2025.07.010_bib14","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.hoc.2025.07.010_bib15","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2016.67.5553","article-title":"Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Khorana","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.07.010_bib16","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/1097-0142(19870615)59:12<2006::AID-CNCR2820591206>3.0.CO;2-B","article-title":"Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group","volume":"59","year":"1987","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2025.07.010_bib17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","article-title":"Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group","volume":"230","author":"Klinkenbijl","year":"1999","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.hoc.2025.07.010_bib18","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jama.299.9.1019","article-title":"Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial","volume":"299","author":"Regine","year":"2008","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.hoc.2025.07.010_bib19","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/cncr.23047","article-title":"Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data","volume":"110","author":"Hazard","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2025.07.010_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jamcollsurg.2008.12.020","article-title":"Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits?","volume":"208","author":"Merchant","year":"2009","journal-title":"J Am Coll Surg"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.010_bib21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1245\/ASO.2006.03.039","article-title":"A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma","volume":"13","author":"Talamonti","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2025.07.010_bib22","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.2007.15.8634","article-title":"Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head","volume":"26","author":"Evans","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2025.07.010_bib23","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1002\/cncr.28117","article-title":"A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer","volume":"119","author":"Kim","year":"2013","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2025.07.010_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ejso.2010.07.003","article-title":"Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response","volume":"36","author":"Turrini","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.07.010_bib25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/SLA.0000000000000251","article-title":"A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma","volume":"260","author":"O\u2019Reilly","year":"2014","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.010_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","article-title":"Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer","volume":"260","author":"Merkow","year":"2014","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.hoc.2025.07.010_bib27","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2013.50.7657","article-title":"Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study","volume":"32","author":"Valle","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2025.07.010_bib28","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1002\/cncr.30163","article-title":"Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer","volume":"122","author":"Mirkin","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.010_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MPA.0b013e31825f3af4","article-title":"Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: a population-based analysis","volume":"42","author":"Amin","year":"2013","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.hoc.2025.07.010_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jamcollsurg.2014.02.023","article-title":"Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer","volume":"219","author":"Cooper","year":"2014","journal-title":"J Am Coll Surg"},{"issue":"6","key":"10.1016\/j.hoc.2025.07.010_bib31","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.surg.2015.06.017","article-title":"Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer","volume":"158","author":"Miura","year":"2015","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.hoc.2025.07.010_bib32","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00000658-199506000-00011","article-title":"Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients","volume":"221","author":"Yeo","year":"1995","journal-title":"Ann Surg"},{"issue":"9293","key":"10.1016\/j.hoc.2025.07.010_bib33","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","article-title":"Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial","volume":"358","author":"Neoptolemos","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2025.07.010_bib34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.sla.0000259391.84304.2b","article-title":"Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma","volume":"246","author":"Raut","year":"2007","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.010_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.surg.2010.07.048","article-title":"NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer","volume":"149","author":"Sahora","year":"2011","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.hoc.2025.07.010_bib36","doi-asserted-by":"crossref","first-page":"e161137","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.hoc.2025.07.010_bib37","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","article-title":"Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas","volume":"127","author":"Evans","year":"1992","journal-title":"Arch Surg"},{"issue":"7","key":"10.1016\/j.hoc.2025.07.010_bib38","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/1097-0142(19931001)72:7<2124::AID-CNCR2820720711>3.0.CO;2-C","article-title":"Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase II study","volume":"72","author":"Yeung","year":"1993","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.010_bib39","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1200\/JCO.1997.15.3.928","article-title":"Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas","volume":"15","author":"Spitz","year":"1997","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2025.07.010_bib40","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1200\/JCO.2007.15.5556","article-title":"Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10073","key":"10.1016\/j.hoc.2025.07.010_bib41","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hoc.2025.07.010_bib42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2012-0435","article-title":"FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience","volume":"18","author":"Faris","year":"2013","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.hoc.2025.07.010_bib43","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1245\/s10434-014-4225-1","article-title":"Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas","volume":"22","author":"Blazer","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2025.07.010_bib44","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch Randomized Phase III PREOPANC Trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"issue":"42","key":"10.1016\/j.hoc.2025.07.010_bib45","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.3748\/wjg.v20.i42.15564","article-title":"Neoadjuvant therapy for pancreas cancer: past lessons and future therapies","volume":"20","author":"Sutton","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.hoc.2025.07.010_bib46","doi-asserted-by":"crossref","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.hoc.2025.07.010_bib47","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/bjs.10870","article-title":"Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer","volume":"105","author":"Versteijne","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.hoc.2025.07.010_bib48","author":"Network"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.010_bib49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.010_bib50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","article-title":"Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine\/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma","volume":"272","author":"Ahmad","year":"2020","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.hoc.2025.07.010_bib51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/SLA.0000000000003270","article-title":"Prognostic factors of survival after neoadjuvant treatment and resection for initially unresectable pancreatic cancer","volume":"273","author":"Klaiber","year":"2019","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.010_bib52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.010_bib53","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/SLA.0000000000003115","article-title":"Comment on \"Interpreting clinical benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer (BRPC)","volume":"270","author":"McCaw","year":"2019","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.hoc.2025.07.010_bib54","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.07.010_bib55","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/s12885-017-3441-z","article-title":"Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas","volume":"17","author":"Katz","year":"2017","journal-title":"BMC Cancer"},{"issue":"3 suppl","key":"10.1016\/j.hoc.2025.07.010_bib56","first-page":"377","article-title":"Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas","volume":"39","author":"Matthew","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.010_bib57","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000518","article-title":"Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer","volume":"42","author":"Kharofa","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.07.010_bib58","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s00268-011-1113-8","article-title":"NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer","volume":"35","author":"Sahora","year":"2011","journal-title":"World J Surg"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:15:32Z","timestamp":1762928132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0889858825000978"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.07.010","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}